Cellular immunotherapy for hematological malignancy: recent progress and future perspectives

References

1. 1.↵
   2. Im A,
   3. Pavletic SZ.

   Immunotherapy in hematologic malignancies: past, present, and future. J Hematol Oncol. 2017; 10: 94.

   OpenUrlCrossRef
2. 2.↵
   2. Filley AC,
   3. Henriquez M,
   4. Dey M.

   CART Immunotherapy: development, success, and translation to malignant gliomas and other solid tumors. Front Oncol. 2018; 8: 453.

   OpenUrlCrossRefPubMed
3. 3.↵
   2. Rotolo A,
   3. Karadimitris A,
   4. Ruella M.

   Building upon the success of CART19: chimeric antigen receptor T cells for hematologic malignancies. Leuk Lymphoma. 2018; 59: 2040–55.

   OpenUrl
4. 4.↵
   2. Rezvani K,
   3. Rouce R,
   4. Liu E,
   5. Shpall E.

   Engineering natural killer cells for cancer immunotherapy. Mol Ther. 2017; 25: 1769–81.

   OpenUrlPubMed
5. 5.↵
   2. Chang YJ,
   3. Zhao XY,
   4. Huang XJ.

   Granulocyte colony-stimulating factor-primed unmanipulated haploidentical blood and marrow transplantation. Front Immunol. 2019; 10: 2516.

   OpenUrl
6. 6.↵
   2. Srivastava S,
   3. Riddell SR.

   Chimeric antigen receptor T cell therapy: challenges to bench-to-bedside efficacy. J Immunol. 2018; 200: 459–68.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   2. Holstein SA,
   3. Lunning MA.

   CAR T-cell therapy in hematologic malignancies: a voyage in progress. Clin Pharmacol Ther. 2020; 107: 112–22.

   OpenUrl
8. 8.↵
   2. Maude SL,
   3. Frey N,
   4. Shaw PA,
   5. Aplenc R,
   6. Barrett DM,
   7. Bunin NJ, et al.

   Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371: 1507–17.

   OpenUrlCrossRefPubMedWeb of Science
9. 9.↵
   2. Lee DW,
   3. Kochenderfer JN,
   4. Stetler-Stevenson M,
   5. Cui YK,
   6. Delbrook C,
   7. Feldman SA et al.

   T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015; 385: 517–28.

   OpenUrlCrossRefPubMedWeb of Science
10. 10.↵
    2. Mullard A.

    FDA approves first CAR T therapy. Nat Rev Drug Discov. 2017; 16: 669.

    OpenUrlCrossRefPubMed
11. 11.↵
    2. Salter AI,
    3. Pont MJ,
    4. Riddell SR.

    Chimeric antigen receptor-modified T cells: CD19 and the road beyond. Blood. 2018; 131: 2621–9.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    2. Porter DL,
    3. Hwang WT,
    4. Frey NV,
    5. Lacey SF,
    6. Shaw PA,
    7. Loren AW, et al.

    Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015; 7: 303ra139.
13. 13.↵
    2. Neelapu SS,
    3. Locke FL,
    4. Bartlett NL,
    5. Lekakis LJ,
    6. Miklos DB,
    7. Jacobson CA, et al.

    Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017; 377: 2531–44.

    OpenUrlCrossRefPubMed
14. 14.↵
    2. Lesch S,
    3. Benmebarek MR,
    4. Cadilha BL,
    5. Stoiber S,
    6. Subklewe M,
    7. Endres S, et al.

    Determinants of response and resistance to CAR T cell therapy. Semin Cancer Biol. 2020; 65: 80–90.

    OpenUrl
15. 15.↵
    2. Greenbaum U,
    3. Mahadeo KM,
    4. Kebriaei P,
    5. Shpall EJ,
    6. Saini NY.

    Chimeric antigen receptor T-cells in B-acute lymphoblastic leukemia: state of the art and future directions. Front Oncol. 2020; 10: 1594.

    OpenUrlPubMed
16. 16.↵
    2. Fry TJ,
    3. Shah NN,
    4. Orentas RJ,
    5. Stetler-Stevenson M,
    6. Yuan CM,
    7. Ramakrishna S, et al.

    CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018; 24: 20–8.

    OpenUrlCrossRefPubMed
17. 17.↵
    2. Pan J,
    3. Niu Q,
    4. Deng B,
    5. Liu S,
    6. Wu T,
    7. Gao Z, et al.

    CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia. Leukemia. 2019; 33: 2854–66.

    OpenUrlPubMed
18. 18.↵
    2. Ormhoj M,
    3. Scarfo I,
    4. Cabral ML,
    5. Bailey SR,
    6. Lorrey SJ,
    7. Bouffard AA, et al.

    Chimeric antigen receptor T cells targeting CD79b show efficacy in lymphoma with or without cotargeting CD19. Clin Cancer Res. 2019; 25: 7046–57.

    OpenUrlAbstract/FREE Full Text
19. 19.↵
    2. Hosen N.

    Chimeric antigen receptor T-cell therapy for multiple myeloma. Cancers (Basel). 2019; 11: 2024.

    OpenUrl
20. 20.↵
    2. Rodriguez-Lobato LG,
    3. Ganzetti M,
    4. Fernandez de Larrea C,
    5. Hudecek M,
    6. Einsele H,
    7. Danhof S.

    CAR T-cells in multiple myeloma: state of the art and future directions. Front Oncol. 2020; 10: 1243.

    OpenUrl
21. 21.↵
    2. Li C,
    3. Mei H,
    4. Hu Y,
    5. Guo T,
    6. Liu L,
    7. Jiang H, et al.

    A bispecific CAR-T cell therapy targeting bcma and CD38 for relapsed/refractory multiple myeloma: updated results from a phase 1 dose-climbing trial. Blood. 2019; 134(Suppl_1): 930.

    OpenUrlCrossRef
22. 22.↵
    2. Zhang H,
    3. Gao L,
    4. Liu L,
    5. Wang J,
    6. Wang S,
    7. Gao L, et al.

    A BCMA and CD19 bispecific CAR-T for relapsed and refractory multiple myeloma. Blood. 2019; 134(Suppl_1): 3147.

    OpenUrl
23. 23.↵
    2. Wang CM,
    3. Wu ZQ,
    4. Wang Y,
    5. Guo YL,
    6. Dai HR,
    7. Wang XH, et al.

    Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory hodgkin lymphoma: an open-label phase I trial. Clin Cancer Res. 2017; 23: 1156–66.

    OpenUrlAbstract/FREE Full Text
24. 24.↵
    2. Ramos CA,
    3. Ballard B,
    4. Zhang H,
    5. Dakhova O,
    6. Gee AP,
    7. Mei Z, et al.

    Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J Clin Invest. 2017; 127: 3462–71.

    OpenUrlPubMed
25. 25.↵
    2. Grover NS,
    3. Savoldo B.

    Challenges of driving CD30-directed CAR-T cells to the clinic. BMC Cancer. 2019; 19: 203.

    OpenUrl
26. 26.↵
    2. Fleischer LC,
    3. Spencer HT,
    4. Raikar SS.

    Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions. J Hematol Oncol. 2019; 12: 141.

    OpenUrl
27. 27.↵
    2. Gomes-Silva D,
    3. Srinivasan M,
    4. Sharma S,
    5. Lee CM,
    6. Wagner DL,
    7. Davis TH, et al.

    CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood. 2017; 130: 285–96.

    OpenUrlAbstract/FREE Full Text
28. 28.↵
    2. Mardiana S,
    3. Gill S.

    CAR T cells for acute myeloid leukemia: state of the art and future directions. Front Oncol. 2020; 10: 697.

    OpenUrl
29. 29.↵
    2. Xu X,
    3. Sun Q,
    4. Liang X,
    5. Chen Z,
    6. Zhang X,
    7. Zhou X, et al.

    Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies. Front Immunol. 2019; 10: 2664.

    OpenUrlPubMed
30. 30.↵
    2. Nie Y,
    3. Lu W,
    4. Chen D,
    5. Tu H,
    6. Guo Z,
    7. Zhou X, et al.

    Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies. Biomark Res. 2020; 8: 18.

    OpenUrlCrossRefPubMed
31. 31.↵
    2. Cao J,
    3. Wang G,
    4. Cheng H,
    5. Wei C,
    6. Qi K,
    7. Sang W, et al.

    Potent anti-leukemia activities of humanized CD19-targeted chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia. Am J Hematol. 2018; 93: 851–8.

    OpenUrlPubMed
32. 32.↵
    2. Zhang T,
    3. Cao L,
    4. Xie J,
    5. Shi N,
    6. Zhang Z,
    7. Luo Z, et al.

    Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis. Oncotarget. 2015; 6: 33961–71.

    OpenUrl
33. 33.↵
    2. Corrigan-Curay J,
    3. Kiem HP,
    4. Baltimore D,
    5. O’Reilly M,
    6. Brentjens RJ,
    7. Cooper L, et al.

    T-cell immunotherapy: looking forward. Mol Ther. 2014; 22: 1564–74.

    OpenUrlCrossRefPubMed
34. 34.↵
    2. Amrolia PJ,
    3. Wynn R,
    4. Hough RE,
    5. Vora A,
    6. Bonney D,
    7. Veys P, et al.

    Phase I study of AUTO3, a bicistronic chimeric antigen receptor (CAR) T-cell therapy targeting CD19 and CD22, in pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL): amelia study. Blood. 2019; 134(Suppl_1): 2620.

    OpenUrl
35. 35.↵
    2. Yang J,
    3. Jiang P,
    4. Zhang X,
    5. Zhu X,
    6. Dong Q,
    7. He J, et al.

    Anti-CD19/CD22 dual CAR-T therapy for refractory and relapsed B-cell acute lymphoblastic leukemia. Blood. 2019; 134(Suppl_1): 284.

    OpenUrl
36. 36.↵
    2. Park JH,
    3. Riviere I,
    4. Gonen M,
    5. Wang X,
    6. Senechal B,
    7. Curran KJ, et al.

    Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018; 378: 449–59.

    OpenUrlCrossRefPubMed
37. 37.↵
    2. Chen YH,
    3. Zhang X,
    4. Cheng YF,
    5. Chen H,
    6. Mo XD,
    7. Yan CH, et al.

    Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. Cytotherapy. 2020; 22: 755–61.

    OpenUrlCrossRef
38. 38.↵
    2. Neelapu SS,
    3. Tummala S,
    4. Kebriaei P,
    5. Wierda W,
    6. Gutierrez C,
    7. Locke FL, et al.

    Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018; 15: 47–62.

    OpenUrlCrossRefPubMed
39. 39.↵
    2. Kenderian SS,
    3. Porter DL,
    4. Gill S.

    Chimeric antigen receptor T cells and hematopoietic cell transplantation: how not to put the CART before the horse. Biol Blood Marrow Transplant. 2017; 23: 235–46.

    OpenUrlPubMed
40. 40.↵
    2. Santomasso BD,
    3. Park JH,
    4. Salloum D,
    5. Riviere I,
    6. Flynn J,
    7. Mead E, et al.

    Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 2018; 8: 958–71.

    OpenUrlAbstract/FREE Full Text
41. 41.↵
    2. Qasrawi A,
    3. Arora R,
    4. Ramlal R,
    5. Munker R,
    6. Hildebrandt GC.

    Allogenic hematopoietic stem cell transplantation for prolonged bone marrow aplasia after chimeric antigen receptor (CAR) T-cell therapy for relapsed diffuse large B-cell lymphoma. Am J Hematol. 2020; 95: E89–91.

    OpenUrl
42. 42.↵
    2. Pan J,
    3. Yang JF,
    4. Deng BP,
    5. Zhao XJ,
    6. Zhang X,
    7. Lin YH, et al.

    High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients. Leukemia. 2017; 31: 2587–93.

    OpenUrlCrossRefPubMed
43. 43.↵
    2. Sabry M,
    3. Lowdell MW.

    Killers at the crossroads: the use of innate immune cells in adoptive cellular therapy of cancer. Stem Cells Transl Med. 2020; 9: 974–84.

    OpenUrl
44. 44.↵
    2. Lupo KB,
    3. Matosevic S.

    Natural killer cells as allogeneic effectors in adoptive cancer immunotherapy. Cancers (Basel). 2019; 11: 769.

    OpenUrl
45. 45.↵
    2. Morandi F,
    3. Yazdanifar M,
    4. Cocco C,
    5. Bertaina A,
    6. Airoldi I.

    Engineering the bridge between innate and adaptive immunity for cancer immunotherapy: focus on γδ T and NK cells. Cells. 2020; 9: 1757.

    OpenUrl
46. 46.↵
    2. Miller JS,
    3. Soignier Y,
    4. Panoskaltsis-Mortari A,
    5. McNearney SA,
    6. Yun GH,
    7. Fautsch SK, et al.

    Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005; 105: 3051–7.

    OpenUrlAbstract/FREE Full Text
47. 47.↵
    2. Bachanova V,
    3. Cooley S,
    4. Defor TE,
    5. Verneris MR,
    6. Zhang B,
    7. McKenna DH, et al.

    Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood. 2014; 123: 3855–63.

    OpenUrlAbstract/FREE Full Text
48. 48.↵
    2. Cooley S,
    3. He F,
    4. Bachanova V,
    5. Vercellotti GM,
    6. DeFor TE,
    7. Curtsinger JM, et al.

    First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia. Blood Adv. 2019; 3: 1970–80.

    OpenUrlAbstract/FREE Full Text
49. 49.↵
    2. Boyiadzis M,
    3. Agha M,
    4. Redner RL,
    5. Sehgal A,
    6. Im A,
    7. Hou JZ, et al.

    Phase 1 clinical trial of adoptive immunotherapy using “off-the-shelf” activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia. Cytotherapy. 2017; 19: 1225–32.

    OpenUrl
50. 50.↵
    2. Zhao XY,
    3. Jiang Q,
    4. Jiang H,
    5. Hu LJ,
    6. Zhao T,
    7. Yu XX, et al.

    Expanded clinical-grade membrane-bound IL-21/4-1BBL NK cell products exhibit activity against acute myeloid leukemia in vivo. Eur J Immunol. 2020; 50: 1374–85.

    OpenUrl
51. 51.↵
    2. Wang CJ,
    3. Huang XJ,
    4. Gong LZ,
    5. Jia JS,
    6. Liu XH,
    7. Wang Y, et al.

    Observation on the efficacy of consolidation chemotherapy combined with allogeneic natural killer cell infusion in the treatment of low and moderate risk acute myeloid leukemia. Zhonghua Xue Ye Xue Za Zhi. 2019; 40: 812–7.

    OpenUrl
52. 52.↵
    2. Rubnitz JE,
    3. Inaba H,
    4. Ribeiro RC,
    5. Pounds S,
    6. Rooney B,
    7. Bell T, et al.

    NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol. 2010; 28: 955–9.

    OpenUrlAbstract/FREE Full Text
53. 53.↵
    2. Nguyen R,
    3. Wu H,
    4. Pounds S,
    5. Inaba H,
    6. Ribeiro RC,
    7. Cullins D, et al.

    A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia. J Immunother Cancer. 2019; 7: 81.

    OpenUrlAbstract/FREE Full Text
54. 54.↵
    2. Munoz Builes M,
    3. Vela Cuenca M,
    4. Fuster Soler JL,
    5. Astigarraga I,
    6. Pascual Martinez A,
    7. Vagace Valero JM, et al.

    Study protocol for a phase II, multicentre, prospective, non-randomised clinical trial to assess the safety and efficacy of infusing allogeneic activated and expanded natural killer cells as consolidation therapy for paediatric acute myeloblastic leukaemia. BMJ Open. 2020; 10: e029642.
55. 55.↵
    2. Passweg JR,
    3. Tichelli A,
    4. Meyer-Monard S,
    5. Heim D,
    6. Stern M,
    7. Kuhne T, et al.

    Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia. 2004; 18: 1835–8.

    OpenUrlCrossRefPubMed
56. 56.↵
    2. Choi I,
    3. Yoon SR,
    4. Park SY,
    5. Kim H,
    6. Jung SJ,
    7. Jang YJ, et al.

    Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study. Biol Blood Marrow Transplant. 2014; 20: 696–704.

    OpenUrlCrossRefPubMed
57. 57.↵
    2. Choi I,
    3. Yoon SR,
    4. Park SY,
    5. Kim H,
    6. Jung SJ,
    7. Kang YL, et al.

    Donor-derived natural killer cell infusion after human leukocyte antigen-haploidentical hematopoietic cell transplantation in patients with refractory acute leukemia. Biol Blood Marrow Transplant. 2016; 22: 2065–76.

    OpenUrlCrossRefPubMed
58. 58.↵
    2. Lee DA,
    3. Denman CJ,
    4. Rondon G,
    5. Woodworth G,
    6. Chen J,
    7. Fisher T, et al.

    Haploidentical natural killer cells infused before allogeneic stem cell transplantation for myeloid malignancies: a phase I trial. Biol Blood Marrow Transplant. 2016; 22: 1290–8.

    OpenUrlPubMed
59. 59.↵
    2. Ciurea SO,
    3. Schafer JR,
    4. Bassett R,
    5. Denman CJ,
    6. Cao K,
    7. Willis D, et al.

    Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation. Blood. 2017; 130: 1857–68.

    OpenUrlAbstract/FREE Full Text
60. 60.↵
    2. Giuliani M,
    3. Poggi A.

    Checkpoint inhibitors and engineered cells: new weapons for natural killer cell arsenal against hematological malignancies. Cells. 2020; 9: 1578.

    OpenUrl
61. 61.↵
    2. Bachiller M,
    3. Battram AM,
    4. Perez-Amill L,
    5. Martin-Antonio B.

    Natural killer cells in immunotherapy: are we nearly there? Cancers (Basel). 2020; 12: 3139.

    OpenUrl
62. 62.↵
    2. Tang X,
    3. Yang L,
    4. Li Z,
    5. Nalin AP,
    6. Dai H,
    7. Xu T, et al.

    First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. Am J Cancer Res. 2018; 8: 1083–9.

    OpenUrlPubMed
63. 63.↵
    2. Liu E,
    3. Marin D,
    4. Banerjee P,
    5. Macapinlac HA,
    6. Thompson P,
    7. Basar R, et al.

    Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 2020; 382: 545–3.

    OpenUrlCrossRefPubMed
64. 64.↵
    2. Xu L,
    3. Chen H,
    4. Chen J,
    5. Han M,
    6. Huang H,
    7. Lai Y, et al.

    The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese society of hematology. J Hematol Oncol. 2018; 11: 33.

    OpenUrl
65. 65.↵
    2. Lv M,
    3. Chang Y,
    4. Huang X.

    Everyone has a donor: contribution of the Chinese experience to global practice of haploidentical hematopoietic stem cell transplantation. Front Med. 2019; 13: 45–56.

    OpenUrl
66. 66.↵
    2. Kanakry CG,
    3. Fuchs EJ,
    4. Luznik L.

    Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat Rev Clin Oncol. 2016; 13: 132.

    OpenUrlCrossRefPubMed
67. 67.↵
    2. Aversa F,
    3. Tabilio A,
    4. Velardi A,
    5. Cunningham I,
    6. Terenzi A,
    7. Falzetti F, et al.

    Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998; 339: 1186–93.

    OpenUrlCrossRefPubMedWeb of Science
68. 68.↵
    2. Huang XJ,
    3. Chen YH,
    4. Xu LP,
    5. Zhang YC,
    6. Liu DH,
    7. Guo NL, et al.

    Combined transplantation of G-CSF primed allogeneic bone marrow cells and peripheral blood stem cells in treatment of severe aplastic anemia. Chin Med J (Engl). 2004; 117: 604–7.

    OpenUrlPubMed
69. 69.↵
    2. Luznik L,
    3. O’Donnell PV,
    4. Symons HJ,
    5. Chen AR,
    6. Leffell MS,
    7. Zahurak M, et al.

    HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008; 14: 641–50.

    OpenUrlCrossRefPubMedWeb of Science
70. 70.↵
    2. Wang Y,
    3. Liu QF,
    4. Xu LP,
    5. Liu KY,
    6. Zhang XH,
    7. Ma X, et al.

    Haploidentical vs. identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood. 2015; 125: 3956–62.

    OpenUrlAbstract/FREE Full Text
71. 71.↵
    2. Wang Y,
    3. Liu QF,
    4. Xu LP,
    5. Liu KY,
    6. Zhang XH,
    7. Ma X, et al.

    Haploidentical vs. Matched-sibling transplant in adults with Philadelphia-negative high-risk acute lymphoblastic leukemia: a biologically phase III randomized study. Clin Cancer Res. 2016; 22: 3467–76.

    OpenUrlAbstract/FREE Full Text
72. 72.↵
    2. Wang Y,
    3. Wang HX,
    4. Lai YR,
    5. Sun ZM,
    6. Wu DP,
    7. Jiang M, et al.

    Haploidentical transplant for myelodysplastic syndrome: registry-based comparison with identical sibling transplant. Leukemia. 2016; 30: 2055–63.

    OpenUrl
73. 73.↵
    2. Ghosh N,
    3. Karmali R,
    4. Rocha V,
    5. Ahn KW,
    6. DiGilio A,
    7. Hari PN, et al.

    Reduced-intensity transplantation for lymphomas using haploidentical related donors vs. HLA-matched sibling donors: a center for international blood and marrow transplant research analysis. J Clin Oncol. 2016; 34: 3141–9.

    OpenUrlAbstract/FREE Full Text
74. 74.↵
    2. Chang YJ,
    3. Huang XJ.

    Is human leukocyte antigen-matched sibling donor transplant always better than haploidentical allograft? Semin Hematol. 2019; 56: 201–8.

    OpenUrl
75. 75.↵
    2. Wang Y,
    3. Liu DH,
    4. Xu LP,
    5. Liu KY,
    6. Chen H,
    7. Chen YH, et al.

    Superior graft-vs.-leukemia effect associated with transplantation of haploidentical compared with HLA-identical sibling donor grafts for high-risk acute leukemia: an historic comparison. Biol Blood Marrow Transplant. 2011; 17: 821–30.

    OpenUrlCrossRefPubMed
76. 76.↵
    2. Chang YJ,
    3. Wang Y,
    4. Liu YR,
    5. Xu LP,
    6. Zhang XH,
    7. Chen H, et al.

    Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis. J Hematol Oncol. 2017; 10: 134.

    OpenUrl
77. 77.↵
    2. Chang YJ,
    3. Wang Y,
    4. Xu LP,
    5. Zhang XH,
    6. Chen H,
    7. Chen YH, et al.

    Haploidentical donor is preferred over matched sibling donor for pre-transplantation MRD positive ALL: a phase 3 genetically randomized study. J Hematol Oncol. 2020; 13: 27.

    OpenUrl
78. 78.↵
    2. Yu S,
    3. Huang F,
    4. Wang Y,
    5. Xu Y,
    6. Yang T,
    7. Fan Z, et al.

    Haploidentical transplantation might have superior graft-vs.-leukemia effect than HLA-matched sibling transplantation for high-risk acute myeloid leukemia in first complete remission: a prospective multicentre cohort study. Leukemia. 2020; 34: 1433–43.

    OpenUrl
79. 79.↵
    2. Guo H,
    3. Guo H,
    4. Chang YJ,
    5. Chang YJ,
    6. Xu LP,
    7. Wang Y, et al.

    Dynamic immune profiling identifies the stronger graft-vs.-leukemia (GVL) effects with haploidentical allografts compared to HLA-matched stem cell transplantation. Cell Mol Immunol. 2021; 18: 1172–85.

    OpenUrl
80. 80.↵
    2. Pei XY,
    3. Zhao XY,
    4. Chang YJ,
    5. Liu J,
    6. Xu LP,
    7. Wang Y, et al.

    Cytomegalovirus-Specific T-cell transfer for refractory cytomegalovirus infection after haploidentical stem cell transplantation: the quantitative and qualitative immune recovery for cytomegalovirus. J Infect Dis. 2017; 216: 945–56.

    OpenUrlCrossRef
81. 81.↵
    2. Zhao XY,
    3. Pei XY,
    4. Chang YJ,
    5. Yu XX,
    6. Xu LP,
    7. Wang Y, et al.

    First-line therapy with donor-derived human cytomegalovirus (HCMV)-specific T cells reduces persistent HCMV infection by promoting antiviral immunity after allogenic stem cell transplantation. Clin Infect Dis. 2020; 70: 1429–37.

    OpenUrl